Rimonabant hydrochloride | CAS# 158681-13-1 | CB1 cannabinoid inverse agonist/antagonist

MedKoo Cat#: 571588 | Name: Rimonabant hydrochloride

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Rimonabant hydrochloride is a potent and selective CB1 cannabinoid inverse agonist/antagonist

Chemical Structure

Rimonabant hydrochloride

CAS#158681-13-1 (HCl)

Theoretical Analysis

MedKoo Cat#: 571588

Name: Rimonabant hydrochloride

CAS#: 158681-13-1 (HCl)

Chemical Formula: C22H22Cl4N4O

Exact Mass: 498.0548

Molecular Weight: 500.25

Elemental Analysis: C, 52.82; H, 4.43; Cl, 28.35; N, 11.20; O, 3.20

Price and Availability

Size	Price	Availability	Quantity
25mg	USD 400.00	2 Weeks
100mg	USD 1,000.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

168273-06-1 (free base) 158681-13-1 (HCl)

Synonym

Rimonabant hydrochloride; Rimonabant HCl; Rimonabant (HCl); Acomplia

IUPAC/Chemical Name

1H-Pyrazole-3-carboxamide, 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-1-piperidinyl-, monohydrochloride

InChi Key

REOYOKXLUFHOBV-UHFFFAOYSA-N

InChi Code

InChI=1S/C22H21Cl3N4O.ClH/c1-14-20(22(30)27-28-11-3-2-4-12-28)26-29(19-10-9-17(24)13-18(19)25)21(14)15-5-7-16(23)8-6-15;/h5-10,13H,2-4,11-12H2,1H3,(H,27,30);1H

SMILES Code

O=C(C1=NN(C2=CC=C(Cl)C=C2Cl)C(C3=CC=C(Cl)C=C3)=C1C)NN4CCCCC4.[H]Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 500.25 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Stuart SA, Butler P, Munafò MR, Nutt DJ, Robinson ES. Distinct Neuropsychological Mechanisms May Explain Delayed- Versus Rapid-Onset Antidepressant Efficacy. Neuropsychopharmacology. 2015 Aug;40(9):2165-74. doi: 10.1038/npp.2015.59. Epub 2015 Mar 5. PubMed PMID: 25740288; PubMed Central PMCID: PMC4487826. 2: Mahmoud MM, Olszewska T, Liu H, Shore DM, Hurst DP, Reggio PH, Lu D, Kendall DA. (4-(Bis(4-fluorophenyl)methyl)piperazin-1-yl)(cyclohexyl)methanone hydrochloride (LDK1229): a new cannabinoid CB1 receptor inverse agonist from the class of benzhydryl piperazine analogs. Mol Pharmacol. 2015 Feb;87(2):197-206. doi: 10.1124/mol.114.095471. Epub 2014 Nov 19. PubMed PMID: 25411367; PubMed Central PMCID: PMC4293445. 3: Elrashidi MY, Ebbert JO. Emerging drugs for the treatment of tobacco dependence: 2014 update. Expert Opin Emerg Drugs. 2014 Jun;19(2):243-60. doi: 10.1517/14728214.2014.899580. Epub 2014 Mar 22. Review. PubMed PMID: 24654737. 4: Marcu J, Shore DM, Kapur A, Trznadel M, Makriyannis A, Reggio PH, Abood ME. Novel insights into CB1 cannabinoid receptor signaling: a key interaction identified between the extracellular-3 loop and transmembrane helix 2. J Pharmacol Exp Ther. 2013 May;345(2):189-97. doi: 10.1124/jpet.112.201046. Epub 2013 Feb 20. PubMed PMID: 23426954; PubMed Central PMCID: PMC3629795. 5: Varga B, Kassai F, Gyertyán I. Interactions of CB1 and mGlu5 receptor antagonists in food intake, anxiety and memory models in rats. Pharmacol Biochem Behav. 2012 Dec;103(2):425-30. doi: 10.1016/j.pbb.2012.09.016. Epub 2012 Sep 28. PubMed PMID: 23026059. 6: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2010 Mar;32(2):133-47. PubMed PMID: 20401351. 7: Rodríguez-Arias M, Manzanedo C, Roger-Sánchez C, Do Couto BR, Aguilar MA, Miñarro J. Effect of adolescent exposure to WIN 55212-2 on the acquisition and reinstatement of MDMA-induced conditioned place preference. Prog Neuropsychopharmacol Biol Psychiatry. 2010 Feb 1;34(1):166-71. doi: 10.1016/j.pnpbp.2009.10.019. Epub 2009 Oct 30. PubMed PMID: 19883712. 8: Cinar R, Szücs M. CB1 receptor-independent actions of SR141716 on G-protein signaling: coapplication with the mu-opioid agonist Tyr-D-Ala-Gly-(NMe)Phe-Gly-ol unmasks novel, pertussis toxin-insensitive opioid signaling in mu-opioid receptor-Chinese hamster ovary cells. J Pharmacol Exp Ther. 2009 Aug;330(2):567-74. doi: 10.1124/jpet.109.152710. Epub 2009 May 15. PubMed PMID: 19448142. 9: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2008 Oct;30(8):643-72. PubMed PMID: 19088949. 10: Tomillero A, Moral MA. Gateways to clinical trials. July-August 2008. Methods Find Exp Clin Pharmacol. 2008 Jul-Aug;30(6):459-95. PubMed PMID: 18850047. 11: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2008 Jun;30(5):383-408. PubMed PMID: 18806898. 12: Esposito I, Proto MC, Gazzerro P, Laezza C, Miele C, Alberobello AT, D'Esposito V, Beguinot F, Formisano P, Bifulco M. The cannabinoid CB1 receptor antagonist rimonabant stimulates 2-deoxyglucose uptake in skeletal muscle cells by regulating the expression of phosphatidylinositol-3-kinase. Mol Pharmacol. 2008 Dec;74(6):1678-86. doi: 10.1124/mol.108.049205. Epub 2008 Sep 18. PubMed PMID: 18801918. 13: Egashira N, Matsuda T, Koushi E, Higashihara F, Mishima K, Chidori S, Hasebe N, Iwasaki K, Nishimura R, Oishi R, Fujiwara M. Delta(9)-tetrahydrocannabinol prolongs the immobility time in the mouse forced swim test: involvement of cannabinoid CB(1) receptor and serotonergic system. Eur J Pharmacol. 2008 Jul 28;589(1-3):117-21. doi: 10.1016/j.ejphar.2008.03.046. Epub 2008 Apr 8. PubMed PMID: 18565508. 14: Moral MA, Tomillero A. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2008 Mar;30(2):149-71. PubMed PMID: 18560631. 15: Bayés M, Rabasseda X. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2008 Jan-Feb;30(1):67-99. PubMed PMID: 18389098. 16: Benamar K, Geller EB, Adler MW. First in vivo evidence for a functional interaction between chemokine and cannabinoid systems in the brain. J Pharmacol Exp Ther. 2008 May;325(2):641-5. doi: 10.1124/jpet.107.135053. Epub 2008 Feb 15. Erratum in: J Pharmacol Exp Ther. 2008 Jun;325(3):1061. PubMed PMID: 18281594. 17: Ward SJ, Lefever TW, Jackson C, Tallarida RJ, Walker EA. Effects of a Cannabinoid1 receptor antagonist and Serotonin2C receptor agonist alone and in combination on motivation for palatable food: a dose-addition analysis study in mice. J Pharmacol Exp Ther. 2008 May;325(2):567-76. doi: 10.1124/jpet.107.131771. Epub 2008 Feb 6. PubMed PMID: 18256173. 18: Oz M, Yang KH, Dinc M, Shippenberg TS. The endogenous cannabinoid anandamide inhibits cromakalim-activated K+ currents in follicle-enclosed Xenopus oocytes. J Pharmacol Exp Ther. 2007 Nov;323(2):547-54. Epub 2007 Aug 6. PubMed PMID: 17682128. 19: Cui YY, D'Agostino B, Risse PA, Marrocco G, Naline E, Zhang Y, Chen HZ, Finance O, Rinaldi-Carmona M, Rossi F, Advenier C. Cannabinoid CB(2) receptor activation prevents bronchoconstriction and airway oedema in a model of gastro-oesophageal reflux. Eur J Pharmacol. 2007 Nov 14;573(1-3):206-13. Epub 2007 Jul 3. PubMed PMID: 17643417. 20: Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2006 Nov;28(9):657-78. PubMed PMID: 17200730.